CirrhosisRx CDS for Liver Cirrhosis

N/A

Waitlist Available

Led By Jin Ge, MD, MBA

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completetion, approximately 36 months

Awards & highlights

No Placebo-Only Group

Summary

This trial compares a new medical system to usual care for hospitalized patients with cirrhosis to see which one works better.

Who is the study for?

This trial is for adults over 18 years old who have been previously diagnosed with cirrhosis, as confirmed by specific diagnosis codes. It's not open to children, those without a proper cirrhosis diagnosis, or patients who aren't hospitalized.

What is being tested?

The study tests CirrhosisRx CDS against usual care to see if it better follows national quality measures and improves outcomes for hospitalized patients with cirrhosis.

What are the potential side effects?

Since this trial involves a decision support system rather than medication, traditional side effects are not applicable. However, there may be risks related to the management of patient care based on the system's recommendations.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completetion, approximately 36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completetion, approximately 36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completetion, approximately 36 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Aggregate adherence to quality measures

Secondary study objectives

Inpatient mortality

Other study objectives

Adoption of CirrhosisRx

Average time spent on CirrhosisRx

Implementation of CirrhosisRx

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: CirrhosisRxExperimental Treatment1 Intervention

Providers in this arm will have access to the CirrhosisRx CDS system, which aggregates and organizes clinical data, presents them in clinically relevant/intuitive fashion for cirrhosis care, and linked to order sets consistent with national guidelines.

Group II: Usual CareActive Control1 Intervention

Providers in this arm will not have access to the CirrhosisRx CDS system.

Do I qualify?Apply below to find out